tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Invivyd Launches SPEAR Study for Long COVID Therapy

Story Highlights
  • Invivyd formed the SPEAR Study Group to explore monoclonal antibody therapy for Long COVID.
  • The initiative aims to evaluate PEMGARDA’s potential in treating Long COVID, impacting Invivyd’s market position.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Invivyd Launches SPEAR Study for Long COVID Therapy

Elevate Your Investing Strategy:

Invivyd ( (IVVD) ) has shared an announcement.

On July 2, 2025, Invivyd announced the formation of the SPEAR Study Group with leading researchers to assess the effects of monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome. This initiative aims to explore the potential of PEMGARDA, a monoclonal antibody, in providing symptom relief for Long COVID, a condition affecting a significant portion of the population. The study group will conduct rigorous clinical trials to evaluate the safety and efficacy of this therapy, potentially unlocking new treatment opportunities for patients and advancing Invivyd’s position in the COVID-19 therapeutic landscape.

The most recent analyst rating on (IVVD) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Invivyd stock, see the IVVD Stock Forecast page.

Spark’s Take on IVVD Stock

According to Spark, TipRanks’ AI Analyst, IVVD is a Neutral.

Invivyd’s overall stock score reflects significant financial and technical weaknesses, marked by ongoing losses and bearish trends. While recent corporate developments offer a glimpse of potential strategic improvement, these are overshadowed by the current financial instability and weak market sentiment.

To see Spark’s full report on IVVD stock, click here.

More about Invivyd

Invivyd, Inc. operates in the biotechnology industry, focusing on the development of monoclonal antibodies for the prevention and treatment of COVID-19. Their primary product, PEMGARDA, is an investigational monoclonal antibody authorized for emergency use in certain immunocompromised individuals for pre-exposure prophylaxis of COVID-19.

Average Trading Volume: 1,997,203

Technical Sentiment Signal: Sell

Current Market Cap: $86.52M

Find detailed analytics on IVVD stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1